ArticleJournal of molecular histology2026
Celastrol attenuates synovial inflammation and experimental arthritis by modulating PTGS2-associated ferroptosis resistance in fibroblast-like synoviocytes.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Rheumatoid arthritis (RA) is characterized by persistent synovial inflammation and aggressive activation of fibroblast-like synoviocytes (FLS). Celastrol has recognized anti-inflammatory activity, but its mechanism in RA remains incompletely defined. This study investigated whether the anti-arthritic effect of celastrol is associated, at least in part, with a PTGS2-associated ferroptosis-resistance pathway in FLS. Potential targets of celastrol in RA were identified through integrated bioinformatic analyses. Collagen-induced arthritis (CIA) rats and primary FLS were used to evaluate the effects of celastrol in vivo and in vitro. Joint pathology, inflammatory mediator expression, oxidative stress, iron accumulation, lipid peroxidation, and ferroptosis-related proteins were assessed. Loss- and gain-of-function experiments were performed to examine the functional role of PTGS2. Bioinformatic screening identified PTGS2 as a candidate functional mediator linking celastrol to RA. In CIA rats, celastrol reduced paw swelling, arthritis severity, synovial hyperplasia, inflammatory cell infiltration, and cartilage and bone destruction. In FLS, celastrol suppressed cell proliferation and migration and decreased the expression of pro-inflammatory cytokines. Mechanistically, the combined changes in intracellular iron, lipid peroxidation, mitochondrial function, and ferroptosis-related proteins supported attenuation of a ferroptosis-resistant phenotype after celastrol treatment. PTGS2 expression was markedly elevated in RA models and was downregulated by celastrol. PTGS2 overexpression attenuated the anti-inflammatory effects of celastrol and reversed several ferroptosis-associated changes, supporting a functional role for PTGS2 in this process. Celastrol alleviates synovial inflammation and experimental arthritis, at least in part, in association with PTGS2 modulation and attenuation of a ferroptosis-resistant phenotype in FLS. To our knowledge, these findings provide experimental evidence linking celastrol, PTGS2-associated regulation, and ferroptosis resistance in RA models.
Indexed as
Identifiers
42525168What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.